Articles published by Amryt Pharma plc
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
January 08, 2023
From Amryt Pharma plc
Via GlobeNewswire
Tickers
AMYT
Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH
January 05, 2023
From Amryt Pharma plc
Via GlobeNewswire
Tickers
AMYT
European Commission approves Mycapssa® for the treatment of Acromegaly
December 05, 2022
From Amryt Pharma plc
Via GlobeNewswire
Tickers
AMYT
Amryt Announces New Patent for Mycapssa®
November 30, 2022
From Amryt Pharma plc
Via GlobeNewswire
Tickers
AMYT
Amryt Reports Q3 2022 Financial and Operational Results
November 03, 2022
From Amryt Pharma plc
Via GlobeNewswire
Tickers
AMYT
Amryt Supports Acromegaly Awareness Day 2022
October 31, 2022
From Amryt Pharma plc
Via GlobeNewswire
Tickers
AMYT
The British Journal of Dermatology Publishes Results from Amryt’s EASE Phase 3 Trial in Epidermolysis Bullosa
October 25, 2022
From Amryt Pharma plc
Via GlobeNewswire
Tickers
AMYT
Amryt Supports Global EB Awareness Week 2022
October 24, 2022
From Amryt Pharma plc
Via GlobeNewswire
Tickers
AMYT
Amryt to Report Q3 2022 Results on November 3, 2022
October 19, 2022
From Amryt Pharma plc
Via GlobeNewswire
Tickers
AMYT
COMP adopts positive opinion on Orphan Disease Designation for Mycapssa® for the treatment of Acromegaly
October 18, 2022
From Amryt Pharma plc
Via GlobeNewswire
Tickers
AMYT
Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin)
October 17, 2022
From Amryt Pharma plc
Via GlobeNewswire
Tickers
AMYT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free